Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at four different antibiotic nasal saline rinses used to treat sinus infections after surgery. The four groups were: mupirocin, tobramycin, levofloxacin, and vancomycin — each mixed into a saltwater nasal rinse. A total of 19 people started the trial across all four groups (12, 1, 5, and 1 respectively), and 17 completed it. The two who did not finish were both in the mupirocin group. The trial was measuring whether participants developed new antibiotic-resistant organisms (germs that become harder to treat), and also tracked changes in participants' self-reported sinus symptoms and physical examination scores. The reported data shows that, for the main outcome — new antibiotic resistance detected by nasal swab — zero participants in the mupirocin, tobramycin, and vancomycin groups developed new resistant organisms, while one participant in the levofloxacin group did. For the symptom survey (scored 0–110, where higher means worse symptoms), the reported changes were: mupirocin −18, tobramycin +14, levofloxacin −25.5, and vancomycin −11. A negative number means scores went down (i.e., reported symptoms decreased), while the tobramycin group showed an increase. For the physical examination score (scored 0–12, where higher means more signs of sinus disease), the reported changes were: mupirocin −5.3, tobramycin −3, levofloxacin −2.4, and vancomycin 0. It is worth noting that most groups were very small — particularly tobramycin and vancomycin, which each had only one participant — so these figures should be understood in that context. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Chronic Rhinosinusitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 80 years old (male or female)
- You have been diagnosed with chronic rhinosinusitis (long-term sinus inflammation)
- You have previously had sinus surgery through the nose (called endoscopic sinus surgery), which included at least two specific procedures on the upper and middle sinuses
- A camera examination of your sinuses shows active infection with mucus/pus, and a swab test has confirmed bacterial growth
- You have signed a written consent form agreeing to take part
- You have not previously been enrolled in this same study
- Your condition has not improved despite receiving the maximum recommended standard medical treatments
Who may not be able to join:
- You have not previously had the specific type of sinus surgery described above
- You are currently taking antibiotic tablets or capsules by mouth
- You have taken antibiotic tablets, capsules, or nose/sinus sprays in the past 14 days
- You are currently taking part in another study involving an investigational (unapproved) drug
- You are currently taking steroid tablets or capsules by mouth
- You have a known allergy to any of the following antibiotics: Tobramycin, Mupirocin, Gentamicin, or Levofloxacin
- You are currently pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Subjects Who Developed Antibiotic Resistance Organisms
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.